FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310106503> ?p ?o ?g. }

• W4310106503 endingPage "7268" @default.
• W4310106503 startingPage "7267" @default.
• W4310106503 abstract "Introduction Belantamab mafodotin (belamaf) is a B-cell maturation antigen-binding antibody-drug conjugate approved as a monotherapy in pretreated patients (pts) with relapsed/refractory multiple myeloma. In pts refractory to immunomodulatory drugs, proteasome inhibitors, and antiCD38, belamaf plus pomalidomide and dexamethasone induced a very good partial response (VGPR) or better rate of 69.2% and a median progression-free survival of 16.2 months (Trudel S, ASH 2021). Corneal examination findings (e.g., keratopathy) and visual acuity changes are common with belamaf, warranting belamaf dose modifications (dose reduction, dose holds) or treatment discontinuation. Here, we evaluate the ocular adverse effects of belamaf and their impact on daily functioning in pts participating in the phase 1/2 BelaRd study. Methods The ongoing, prospective, open-label, 2-part, phase 1/2 BelaRd study (NCT04808037) aims to enroll 66 adult pts with TI NDMM. In Part 1 of the study (dose selection), 18 pts are randomized (1:1:1) in 3 cohorts to receive belamaf 2.5, 1.9, or 1.4 mg/kg doses by intravenous infusion once every 8 weeks (Q8W) plus Rd and the safety/tolerability of the combination is evaluated for pts with ≥4 weeks of follow up. As a safety review found no unexpected findings, an additional 6 pts were enrolled in each dose cohort to select the belamaf recommended phase 2 dose (RP2D). Part 2 (dose expansion; not initiated) will further evaluate the safety and clinical activity of belamaf RP2D plus Rd. Ocular assessments include best corrected visual acuity (BCVA), using Snellen chart and manifest refraction, and corneal exam using slit lamp microscopy. Ocular symptoms are classified by Common Terminology Criteria for Adverse Events and dry eye disease severity and vision-related functioning is assessed with the patient-reported Ocular Surface Disease Index (OSDI). In Part 1 of the study, severity of corneal events is assessed with the Keratopathy Visual Acuity scale. This descriptive analysis included all Part 1 pts from the BelaRd study (data cut-off: 24 June 2022). Results Thirty-six pts were included in this analysis, who were followed up for a median of 9.5 months (range 3.2-15.4). At baseline (cycle 1 day 1), all pts had ocular comorbidities. During follow-up, most of OSDI assessments indicated that there was an impact of study treatment on activities of daily living (ADLs) 'some' or 'none of the time', while only <2.0% of OSDI assessments indicated the impact was 'all' or 'most of the time' (Table). The most common any grade (gr) ocular adverse events (OAEs) across cohorts were dry eye and visual acuity reduced. Gr 3 OAEs were observed only for visual acuity reduced, visual impairment, and cataract; no Gr 4 OAEs were observed. Belamaf doses skipped due to OAEs per the total number of planned belamaf administrations were 23/68 (33.8%), 15/73 (20.5%), and 10/69 (14.5%) in cohorts 2.5, 1.9, and 1.4 mg/kg, respectively. For the entire pt population, median times to resolution of keratopathy and BCVA change from baseline were 2.1 months (range 0.7-11.1) and 2.0 months (range 0.3-6.9), respectively; across cohorts, numerically similar median times to resolution were observed for each OAE Conclusions No new ocular safety signals were observed with belamaf plus Rd in the upfront treatment of TI pts with NDMM; the observed OAEs were within the anticipated range with the use of belamaf. Keratopathy and BCVA change from baseline were resolved by a median of ~2 months; for each of these OAEs, similar times to resolution were recorded, across dose cohorts. Belamaf plus Rd had a minor impact on ADLs, with the patients receiving 1.4 and 1.9 mg/kg doses being the least impacted. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310106503 created "2022-11-30" @default.
• W4310106503 creator A5009776953 @default.
• W4310106503 creator A5012405296 @default.
• W4310106503 creator A5018522443 @default.
• W4310106503 creator A5028178125 @default.
• W4310106503 creator A5033282728 @default.
• W4310106503 creator A5033971808 @default.
• W4310106503 creator A5041407463 @default.
• W4310106503 creator A5045531432 @default.
• W4310106503 creator A5047107290 @default.
• W4310106503 creator A5059359090 @default.
• W4310106503 creator A5065602436 @default.
• W4310106503 creator A5071485489 @default.
• W4310106503 creator A5083511911 @default.
• W4310106503 creator A5088691462 @default.
• W4310106503 creator A5090511737 @default.
• W4310106503 date "2022-11-15" @default.
• W4310106503 modified "2023-10-18" @default.
• W4310106503 title "Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial" @default.
• W4310106503 doi "https://doi.org/10.1182/blood-2022-162208" @default.
• W4310106503 hasPublicationYear "2022" @default.
• W4310106503 type Work @default.
• W4310106503 citedByCount "0" @default.
• W4310106503 crossrefType "journal-article" @default.
• W4310106503 hasAuthorship W4310106503A5009776953 @default.
• W4310106503 hasAuthorship W4310106503A5012405296 @default.
• W4310106503 hasAuthorship W4310106503A5018522443 @default.
• W4310106503 hasAuthorship W4310106503A5028178125 @default.
• W4310106503 hasAuthorship W4310106503A5033282728 @default.
• W4310106503 hasAuthorship W4310106503A5033971808 @default.
• W4310106503 hasAuthorship W4310106503A5041407463 @default.
• W4310106503 hasAuthorship W4310106503A5045531432 @default.
• W4310106503 hasAuthorship W4310106503A5047107290 @default.
• W4310106503 hasAuthorship W4310106503A5059359090 @default.
• W4310106503 hasAuthorship W4310106503A5065602436 @default.
• W4310106503 hasAuthorship W4310106503A5071485489 @default.
• W4310106503 hasAuthorship W4310106503A5083511911 @default.
• W4310106503 hasAuthorship W4310106503A5088691462 @default.
• W4310106503 hasAuthorship W4310106503A5090511737 @default.
• W4310106503 hasBestOaLocation W43101065031 @default.
• W4310106503 hasConcept C126322002 @default.
• W4310106503 hasConcept C143998085 @default.
• W4310106503 hasConcept C197934379 @default.
• W4310106503 hasConcept C2776063141 @default.
• W4310106503 hasConcept C2776364478 @default.
• W4310106503 hasConcept C2779609412 @default.
• W4310106503 hasConcept C2780401358 @default.
• W4310106503 hasConcept C31760486 @default.
• W4310106503 hasConcept C535046627 @default.
• W4310106503 hasConcept C71924100 @default.
• W4310106503 hasConceptScore W4310106503C126322002 @default.
• W4310106503 hasConceptScore W4310106503C143998085 @default.
• W4310106503 hasConceptScore W4310106503C197934379 @default.
• W4310106503 hasConceptScore W4310106503C2776063141 @default.
• W4310106503 hasConceptScore W4310106503C2776364478 @default.
• W4310106503 hasConceptScore W4310106503C2779609412 @default.
• W4310106503 hasConceptScore W4310106503C2780401358 @default.
• W4310106503 hasConceptScore W4310106503C31760486 @default.
• W4310106503 hasConceptScore W4310106503C535046627 @default.
• W4310106503 hasConceptScore W4310106503C71924100 @default.
• W4310106503 hasIssue "Supplement 1" @default.
• W4310106503 hasLocation W43101065031 @default.
• W4310106503 hasOpenAccess W4310106503 @default.
• W4310106503 hasPrimaryLocation W43101065031 @default.
• W4310106503 hasRelatedWork W1699374300 @default.
• W4310106503 hasRelatedWork W1966525515 @default.
• W4310106503 hasRelatedWork W1988784378 @default.
• W4310106503 hasRelatedWork W2025192618 @default.
• W4310106503 hasRelatedWork W2034815165 @default.
• W4310106503 hasRelatedWork W2074205062 @default.
• W4310106503 hasRelatedWork W2090603150 @default.
• W4310106503 hasRelatedWork W2192430028 @default.
• W4310106503 hasRelatedWork W2378175831 @default.
• W4310106503 hasRelatedWork W2430400806 @default.
• W4310106503 hasVolume "140" @default.
• W4310106503 isParatext "false" @default.
• W4310106503 isRetracted "false" @default.
• W4310106503 workType "article" @default.